RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report

Kei Morikawa1*, Hiroshi Handa1, Junko Ueno1, Hajime Tsuruoka1, Takeo Inoue1, Naoki Shimada2, Junki Koike2, Seiji Nakamura3, Yoshiharu Sato3 and Masamichi Mineshita1

1Division of Respiratory Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 2Department of Pathological Diagnosis, St. Marianna University School of Medicine, Kawasaki, Japan, 3DNA Chip Research Inc., Tokyo, Japan

Personalized medicine using molecular-targeted drugs to achieve better therapeutic response and long-term prognosis is common practice for lung cancer treatment. However, in cases before gene batch tests were available, medical treatment continued without the detection of rare mutations. We report a sixty-seven-old year man diagnosed with adenocarcinoma T1cN3M1a, stage IVA. Initial screening performed 7 years earlier using EGFR mutation and ALK immunohistochemical tests were negative. Although first-line cytotoxic combination chemotherapy was remarkably effective, a gradual regression of the primary lesion was noted. After a recent bronchoscopic re-biopsy, RET fusion was detected by gene panel test. In addition, we were able to confirm RET from FFPE specimens obtained from 7-year-old pleural effusion cell blocks. Subsequent administration of the molecular-targeted drug selpercatinib, was highly effective for the primary lesion and all metastatic lesions including brain metastases. We describe a case of RET fusion-positive lung cancer where molecular targeted therapy and cytotoxic drug showed a drastic response and long-term therapy was well maintained. Next generation sequencing was able to correctly diagnose RET fusion mutation using re-biopsy specimen after going undiagnosed for 7 years.

KEYWORDS
RET mutation detected by re-biopsy case report, gene mutation, re-biopsy, RET fusion lung cancer, selpercatinib
Introduction

Personalized medicine for lung cancer patients using molecular-targeted drugs and immune checkpoint inhibitors has become widespread due to their high response rates and long-term prognosis (1–3). To date, epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion genes, ROS1, BRAF, MET exon 14 skipping mutations, RET fusion genes and their corresponding molecular-targeted drugs have been approved by the Food and Drug Administration (FDA). Furthermore, KRAS mutation, EGFR and HER2 exon 20 insertion and their corresponding molecular-targeted drugs will soon be available.

However, in cases before gene batch tests were available, the patient’s medical treatment would have progressed without the detection of rare mutations. It is presumed that malignancy and the therapeutic effects of cytotoxic drugs differ depending on the type of gene mutation (4, 5). Therefore, even in cases with mutation-positive advanced lung adenocarcinoma, long-term clinical courses can be maintained without the administration of molecular-targeted drugs. In particular, even in cases where the initial treatment was successful, the initial sample might not be suitable for gene panel testing due to the deterioration of nucleic acid quality over time. Furthermore, it can be difficult to select the same location for re-biopsy since the lesion might have been altered by treatment. Herein, we report a rare case in where RET fusion was detectable by gene panel test after re-biopsy seven years after the initial diagnosis. Sequential administration of the molecular-target drug selpercatinib showed a drastic response.

Case report

A 67-year-old male, never smoker with no remarkable medical history, was referred to our hospital with a massive left pleural effusion (Figure 1A). The cytological evaluation of the left pleural effusion was class V adenocarcinoma, consistent with the cell block pathological assessment. Pleurodesis using talc dilated the lungs well, and a 25 × 17 mm nodule at the left S1 + 2 was presumed to be the primary lesion (Figure 1B). Clinically, he was diagnosed with adenocarcinoma T1cN3M1a, stage IVA. Initial gene mutation screening seven years earlier using Cobas® EGFR mutation and ALK immunohistochemical (IHC) tests were negative.

First-line treatment included carboplatin + pemetrexed + bevacizumab, and although a near complete response (CR) was obtained after 4 courses, nasal bleeding continued, and only pemetrexed was administered for maintenance therapy. CR was achieved over 25 courses of maintenance therapy (Figure 1C), but treatment was temporarily terminated due to a slight deterioration of renal function. One year post treatment, CT showed a slight progression in the primary lesion (Figure 1D), but the speed of regrowth was slow. One year after the progression was confirmed by CT (Figure 1E), pemetrexed monotherapy was resumed, and the primary lesion and lymph nodes decreased (Figure 1F). However, after 32 courses of maintenance therapy, a rapid systemic progression was noted. Due to the primary lesion regrowth (Figure 1G), contralateral lung metastasis, multiple liver metastases, a right adrenal metastasis, and multiple brain metastases (Figures 2A, B), adjustments to his treatment were necessary.
Bronchoscopic re-biopsy of the primary lesion revealed class V adenocarcinoma cytologically, and histological assessment confirmed this result. Oncomine™ Dx Target Test confirmed the patient was RET fusion gene-positive, and the RET inhibitor selpercatinib 240 mg was administered the following day. On day 13, CT revealed a good systemic response with all metastatic lesions, including brain metastases (Figures 2C, D), compared with baseline imaging (Figure 1H). Selpercatinib with a dose reduction (160 mg/day) for grade 2 elevated liver enzymes was continued. A high sensitivity next generation sequencing (NGS) panel system: lung cancer compact panel, with RNA assay using cytological brushing solution (6, 7), confirmed the fusion gene KIF5B exon 15; RET exon 12 (K15RET12). We could further confirm RET from formalin-fixed paraffin-embedded (FFPE) specimens from 7-year-old pleural effusion cell blocks (Figures 3A, B), which were morphologically similar to re-biopsy sample in terms of malignant cells with large nucleoli (Figures 3C, D). RNA (1256 ng) was collected from the initial cell block sample, with an RNA integrated number (RIN) value of 4.8. A K15RET12 fusion peak was detected by single-plex polymerase chain reaction (PCR) (Figure 3) and NGS assay.

Finally, we provide additional information on PCR and NGS techniques. SYBR-Green real-time PCR assay with melting curve analysis was performed to detect RET fusion detection from archive cellblock sample. KOD SYBR® qPCR/RT set (Toyobo) was used for reverse transcription and real time PCR. These assays were performed according to the manufacturer’s protocols. Non-tumor wild type sample was assayed in parallel as negative control. Peak call of 78 degree from melting curve chromatogram is the criteria for the detection of fusion positive. Moreover, sequence of fusion boundary was confirmed by NGS sequencing (Illumina Miseq 150 paired-end) of qPCR product.

Lung cancer compact panel assay was also performed for archive first diagnostic sample. KIF5b-exon15_RET-exon12 fusion was also detected from this analysis. Moderate signal intensity of fusion variant was obtained from this assay (70 fusion boundary-positive reads out of 1,335 total sequencing reads). Lung cancer compact panel assay was performed
according to the protocol described previously (8). Limit of detection of RET fusion detection by lung cancer compact panel is no more than 1% variant allele frequency.

**Discussion**

Conventionally, gene mutations have been identified by the single-plex PCR method for individual gene mutations. The PCR, which has high sensitivity and specificity, a short turn-around time, and is relatively inexpensive, has become widespread mainly for the detection of EGFR. However, with the discovery of various lung cancer driver genes over the last five years, it is impractical to test single gene mutations sequentially due to time and sample consumption constraints. In 2017, the gene panel test, Oncomine Dx Target Test Multi-CDx system (Thermo Fisher Scientific, San Jose, CA, USA), which can simultaneously evaluate 46 cancer-related genes, was one of the first NGS panels for non-small cell lung cancer testing approved by the FDA (9). However, this batch test requires sufficient amounts of malignant cells in the collected tissue sample and qualified sample handling. Moreover, if a significant amount of time has passed since collection, the sample is often unsuitable for gene panel testing due to the deterioration of nucleic acid quality. Since the initial diagnosis in this case was made over 7 years ago, it was assumed that the nucleic acid quality would have deteriorated over that time. Therefore, re-biopsy of the primary lesion was performed.

This was a rare case where cytotoxic chemotherapy, and subsequent maintenance therapy, was remarkably effective for the primary lesion. Generally, progression-free survival for cytotoxic chemotherapy in advanced-stage gene mutation-positive lung adenocarcinoma is about 6 months (4, 5), and it is not often possible to continue treatment for more than one year. Even when treatment is continued beyond-progressive disease (beyond-PD), in most cases, treatment adjustments are unavoidable due to the systemic exacerbation of the disease. The prognosis for gene mutant lung adenocarcinoma without the use of molecular-targeted drugs is generally poor, but there are cases in which cancer development is observed over a very long period of time. In particular, RET fusion lung cancer has been reported to show a slower clinical course (10, 11). Hence, as in our patient, there are a number of cases where rare mutations have not been detected over long-term clinical courses.

Selpercatinib, similar to other molecular-targeted therapies, had sufficient systemic effects (12, 13), including brain metastases (14). In general, first-line treatment for gene mutation-positive lung adenocarcinoma is the corresponding molecular-targeted drug; however, this case suggests that the order of drugs used may be important when aiming for the longest overall survival by sequence therapy (15). In a phase 3 study of selpercatinib for RET-positive lung cancer, the efficacy of molecular-targeted drugs, in addition to the therapeutic effects
of cytotoxic drugs will be clarified (16). It is noteworthy that we were able to detect RET fusion by extracting RNA from 7-year-old pleural effusion cell blocks, which contained a low percentage of malignant cells.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. The research gene analysis was with ethics approval (HREC ID 4814).

Author contributions

KM had full access to data in this case report and takes responsibility for the integrity and accuracy of data analysis. KM, HH, JU, HT and TI contributed to bronchoscopic examination and interpretation. NS, JK, SN and YS contributed to pathological evaluation and genetic analysis. KM and MM contributed to the scientific review and final approval of this manuscript. All authors contributed to the article and approved the submitted version.

References

1. Mark GK, Bruce EJ, Lynne DB, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA (2014) 311(19):1998–2006. doi: 10.1001/jama.2014.3741
2. Gambardella V, Tarazona N, Cevallo JM, Lombardi P, Huerta M, Rosello S, et al. Personalized medicine: Recent progress in cancer therapy. Cancers (2020) 12 (4):1009. doi: 10.3390/cancers12041009
3. Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group. Ann Oncol (2020) 31(11):1491–505. doi: 10.1016/annonc.2020.07.014
4. Sorta JC, Tan DSW, Chari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet (2017) 389(10072):917–29. doi: 10.1016/S0140-6736(17)30123-X
5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 13(3):239–46. doi: 10.1016/S1470-2045(11)70393-X
6. Morikawa K, Kida H, Handa H, Inoue T, Saiji H, Koshe J, et al. A prospective validation study of lung cancer gene panel testing using cytological specimens. Cancers (2022) 14(15):3784. doi: 10.3390/cancers14153784
7. Morikawa K, Kinoshita K, Kida H, Inoue T, Mineshita M. Preliminary results of NGS gene panel test using NSCLC sputum cytology and therapeutic effect using corresponding molecular-targeted drugs. Gene (2022) 13(5):812
8. Kato K, Okami J, Nakamura H, Homma K, Sato Y, Nakamura S, et al. Analytical performance of a highly sensitive system to detect gene variants using next-generation sequencing for lung cancer companion diagnostics. medRxiv (2021). doi: 10.1101/2021.10.13.21264976
9. FDA U. Summary of safety and effectiveness data for oncomine dx target test (2017). Available at: https://www.accessdata.fda.gov/drugs_docs/pdf16/P160045B.pdf (Accessed 27 March 2022).
10. Drilon A, Bergaglini I, Delaoso L, Sabari J, Woo KM, Ploedkowski A. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Ann Oncol (2016) 27(7):1286–91. doi: 10.1093/annonc/mdv163
11. Shen T, Pu X, Wang L, Yu Z, Li J, Zhang Y, et al. Association between RET fusions and efficacy of pemetrexed-based systemic therapies in RET-rearranged lung cancers. Oncologist (2020) 25(5):e349–54. doi: 10.1615/clinont.2020.02.006
12. Illini O, Hochmair MJ, Fabikan H, Weinlinger C, Tufman A, Swalduz A, et al. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Ther Adv Med Oncol (2021) 13:17588359211019675. doi: 10.1177/17588359211019675

Acknowledgments

The authors thank Mr. Jason Tonge from St. Marianna University School of Medicine for the linguistic review of this manuscript.

Conflict of interest

Author SN and YS was employed by DNA Chip Research Inc. The research gene analysis of this case was conducted by DNA Chip Research Inc., Tokyo, Japan.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
13. Hess LM, Han Y, Zhu YE, Bhandari NR, Sireci A. Characteristics and outcomes of patients with RET-fusion-positive non-small lung cancer in real-world practice in the United States. *BMC Cancer* (2021) 21(1):28. doi: 10.1186/s12885-020-07714-3

14. Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, et al. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. *Clin Cancer Res* (2021) 27(15):4160–7. doi: 10.1158/1078-0432.CCR-21-0800

15. Knetki-Wroblewska M, Wojas-Krawczyk K, Kowalski DM, Krzakowski M. Non-Small-Cell Lung cancer patients with coexistence of high PD-L1 expression and RET fusion—which path should we follow? case reports and literature review. *J Clin Med* (2022) 11(6):1630. doi: 10.3390/jcm11061630

16. Solomon BJ, Zhou CC, Drilon A, Park K, Wolf J, Elamin Y, et al. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. *Future Oncol* (2021) 17(6):763–73. doi: 10.2217/fon-2020-0935